Revolution Medicines' stock fell nearly 20% in overnight trading after Merck shelved acquisition talks due to price disagreements, crossing below the 20-day SMA.
The discussions between Merck and Revolution Medicines have ceased after failing to agree on a $30 billion valuation, leading to significant investor uncertainty. Despite this setback, analysts believe there may still be opportunities for negotiations to restart or for other potential buyers to emerge, particularly with the upcoming clinical data releases for Revolution's experimental drug daraxonrasib, which is in late-stage trials targeting multiple mutations in RAS genes.
The end of the acquisition talks has raised concerns among investors about Revolution's future prospects, but the market sentiment remains somewhat bullish, as retail interest has surged significantly. Investors are closely watching for any developments that could influence the company's trajectory.
Wall Street analysts forecast RVMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVMD is 86.00 USD with a low forecast of 67.00 USD and a high forecast of 147.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
Wall Street analysts forecast RVMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVMD is 86.00 USD with a low forecast of 67.00 USD and a high forecast of 147.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Buy
0 Hold
0 Sell
Strong Buy
Current: 98.200
Low
67.00
Averages
86.00
High
147.00
Current: 98.200
Low
67.00
Averages
86.00
High
147.00
Oppenheimer
Jay Olson
Outperform
maintain
$75 -> $150
2026-01-27
New
Reason
Oppenheimer
Jay Olson
Price Target
$75 -> $150
AI Analysis
2026-01-27
New
maintain
Outperform
Reason
Oppenheimer analyst Jay Olson raised the firm's price target on Revolution Medicines to $150 from $75 and keeps an Outperform rating on the shares. The firm notes Revolution has been the subject of substantial M&A speculation entering 2026 as it sees multiple milestones this year that could sweeten a potential deal. Oppenheimer's biotech M&A analysis shows increasing strategic demand for novel approaches to areas of high unmet need while oncology remains dominant, supporting Oppenheimer as an attractive potential takeout candidate.
JPMorgan
Brian Cheng
Overweight
maintain
$92
2026-01-26
New
Reason
JPMorgan
Brian Cheng
Price Target
$92
2026-01-26
New
maintain
Overweight
Reason
JPMorgan analyst Brian Cheng expects Revolution Medicines shares to trade "meaningfully lower" today after the Wall Street Journal reported Merck (MRK) is no longer in talks to acquire the company. The stock in premarket trading is down 21%, or $25.16, to $92.47. Feedback from investor discussions suggest the shares could trade into the $90s-$100s range, the analyst tells investors in a research note. JPMorgan, however, believes the report could also be perceived as a positive read-through to Revolution's level of confidence in the outcome for daraxonrasib. It reiterates the stock as a top pick for 2026 with an Overweight rating and $92 price target.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RVMD
Unlock Now
Stifel
Buy
maintain
$170
2026-01-25
Reason
Stifel
Price Target
$170
2026-01-25
maintain
Buy
Reason
Stifel expects buyers of Revolution Medicines (RVMD) to step into the stock on weakness after the Wall Street Journal reported that Merck (MRK) is no longer in discussions to acquire the company. Stifel would be surprised to see the stock settle meaningfully below $100 per share. This "M&A clearing event will be viewed as a buying opportunity for many sector specialists," the analyst tells investors in a research note. The firm expects investor focus to shift now to Revolution's "catalyst rich" 2026. It keeps a Buy rating on the shares with a $170 price target.
Stifel
Buy
upgrade
$85 -> $170
2026-01-22
Reason
Stifel
Price Target
$85 -> $170
2026-01-22
upgrade
Buy
Reason
Stifel raised the firm's price target on Revolution Medicines to $170 from $85 and keeps a Buy rating on the shares. In an M&A scenario, the firm's target values Revolution at about $36B and at a deal valuation "well within" the historic biotech M&A range, the analyst tells investors. In addition to the scarcity value of pan-RAS inhibitors, the firm believes the pipeline has a lot of value that is not recognized in five-year forward estimates, which it argues could give Revolution "substantial leverage in M&A negotiations," but also drive meaningful near-term upside should the company remain independent.
About RVMD
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
